We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Supercomputing Technology Creates Opportunities for Drug Discovery

By LabMedica International staff writers
Posted on 25 Jan 2011
A faster and cost-effective technique to scan molecular databases could put scientists on the fast track to developing new drug treatments.

A team led by Dr. More...
Jerome Baudry of the University of Tennessee and the US Department of Energy's Oak Ridge National Laboratory (ORNL) Center for Molecular Biophysics (Oak Ridge, USA) adapted a widely used existing software to allow supercomputers such as ORNL's Jaguar to filter through massive molecular databases and pinpoint chemical compounds as potential drug candidates.

The research was published online December 2010 online ahead of print in the Journal of Computational Chemistry. "Our research is the missing link between supercomputers and the huge data available in molecular databases like the Human Genome Project,” Dr. Baudry said. "We have an avalanche of data available to us, and now we need to translate that data into knowledge.”

Such translation is vital for the first stages of drug development, in which researchers look for applicable chemicals that interact with a target in the body, typically a protein. If the chemical is suitable, it attaches onto the protein and produces a desirable effect in the cell. However, with thousands of known proteins and millions of chemicals as potential drugs, the number of possible combinations is enormous. "It is very expensive and time-consuming to measure these interactions experimentally,” Dr. Baudry stated. "But with supercomputers, we can process millions of molecules a day.”

The fast and efficient processing of molecules gives scientists an opportunity to take risks on previously unexamined drug candidates, which could lead to diverse and novel classes of drugs. "Before, we threw away a lot of information because molecules did not have a preferred profile,” Dr. Baudry noted. "Now, every molecule can be examined without worrying about wasting resources.”

The scientists have already begun work to launch the research into reality through a new collaboration supported by the US National Institutes of Health (Bethesda, MD, USA). The project team plans to put the computational development to work on ORNL supercomputers to search for chemicals that could treat prostate cancer.

"Our development work is the computational equivalent of building the Saturn V rocket,” Dr. Baudry concluded. "Now we want to fly it to the moon.”

Related Links:

Oak Ridge National Laboratory Center for Molecular Biophysics




Gold Member
Serological Pipets
INTEGRA Serological Pipets
Portable Electronic Pipette
Mini 96
Specimen Radiography System
TrueView 200 Pro
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.